Is Sutro Biopharma (STRO) overvalued? · rev $62.0M
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
This page asks whether Sutro Biopharma (STRO) looks expensive on cached numbers — not a short thesis.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
STRO currently screens at market cap $470.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next STRO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the STRO stock page for the full model, not this heading.
Not investment advice.